There are 2949 resources available
165MO - Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
Presenter: Joyce O'Shaughnessy
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
166MO - A phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD201 to trastuzumab in HER2+ early breast cancer patients (TROIKA)
Presenter: Pivot Xavier
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
167MO - Longitudinal evaluation of serum assessed non-adherence to tamoxifen (TAM) among premenopausal patients (pts) in the prospective multicenter CANTO cohort
Presenter: Barbara Pistilli
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
168MO - GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status
Presenter: Theresa Link
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
169MO - Development and validation of a magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with breast cancer: A multicenter cohort study
Presenter: Herui Yao
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
886MO - Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Presenter: Pier Luigi Zinzani
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
280MO - Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
Presenter: Pauline Corbaux
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
281MO - Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
Presenter: Marcela Carausu
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
282MO - Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer (GAP): A multicenter, randomized, open-label, phase III trial
Presenter: Xichun Hu
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
283MO - Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial
Presenter: Nicholas Turner
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast